What precisely is So Extraordinary On Z-VAD-FMK?

We will report consent data (number and percentage for each category) for the following groups: Prior informed consent from trial participant Prior informed http://www.selleck.cn/products/z-vad-fmk.html consent from legal surrogate Delayed consent from trial participant Delayed consent from legal surrogate Consent from other legal body before or after trial participant's death No consent �C data withdrawn We will report data (number and percentage for each category) for the following categories of trial participants for whom study treatment was permanently discontinued: Trial participants for whom informed consent was withdrawn Trial participants for whom informed consent was withheld Trial treatment discontinued because of transfer to the operating theatre http://www.selleckchem.com/products/sch772984.html and EGDT unable to be continued Study treatment discontinued because of transfer to another hospital during the 6?h EGDT period Trial treatment discontinued because of cardiopulmonary arrest Trial treatment discontinued because of other reason A Fisher's exact test will be used to assess the effect of treatment allocation on 90 day all-cause mortality. The numbers at risk in each group and the number and proportion of events observed will be reported, as well as the equivalent absolute risk difference and RRR, and each corresponding 95% confidence interval (CI). We will report as secondary outcomes, effect estimates derived from multivariable logistic regression models with 90 day all-cause mortality as the dependent variable. These models will adjust for the independent baseline covariates of age, APACHE II score, SBP http://www.selleckchem.com/products/dabrafenib-gsk2118436.html corresponding 95% CI and P-values, will be obtained from Cox proportional hazards models incorporating treatment group alone, and also the independent covariates used in the multivariable logistic models as detailed above. The duration of ED and hospital stay will be calculated from the time of randomisation respectively, and the duration of ICU stay from the time of ICU admission. These durations will be summarised as median and IQR, and compared between treatment groups using a Wilcoxon rank-sum test. Similar analyses will occur for the duration of mechanical ventilation, vasopressor support and renal replacement therapy.